Barinthus Biotherapeutics plc (NASDAQ:BRNS – Get Free Report) was the target of a large growth in short interest in January. As of January 15th, there was short interest totalling 12,400 shares, a growth of 134.0% from the December 31st total of 5,300 shares. Based on an average trading volume of 49,800 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.0% of the company’s stock are short sold.
Analysts Set New Price Targets
Separately, HC Wainwright reduced their target price on Barinthus Biotherapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a report on Monday, January 13th.
Get Our Latest Research Report on Barinthus Biotherapeutics
Barinthus Biotherapeutics Price Performance
Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.23. The firm had revenue of $14.97 million during the quarter. During the same period in the prior year, the firm earned ($0.37) earnings per share. As a group, equities analysts forecast that Barinthus Biotherapeutics will post -1.38 EPS for the current year.
Barinthus Biotherapeutics Company Profile
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.
Featured Articles
- Five stocks we like better than Barinthus Biotherapeutics
- NYSE Stocks Give Investors a Variety of Quality Options
- Nebius Group: Market Overreaction or Real AI Disruption?
- Differences Between Momentum Investing and Long Term Investing
- The Best Way to Invest in Gold Is…
- EV Stocks and How to Profit from Them
- Why Nike Stock Could Be 2025’s Top Comeback Play
Receive News & Ratings for Barinthus Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Barinthus Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.